Ramy Sedhom: Real-world challenges in CapeOX tolerability for localized colorectal cancer
Ramy Sedhom, Director of Medical Oncology and Palliative Care at Penn Medicine Princeton Health, shared a post on X about a paper by Veronica Mears et al. published in JCO Oncology Practice:
“Credit to JCO Oncology Practice for publishing this study.
Small, single-institution experience but likely informative of our collective experience
- <50% of patients completed all planned CapeOX cycles
- ~30% experience grade III or greater AEs
- ~18% hospitalized during treatment.
What can we learn from this work?
- ‘real world’ experiences differ from trials
- how we frame Rx matters
Patients are scared of recurrence, and yet chemo is hard to tolerate. Always good to remind patients dose-reductions, dose-interruptions, and early discontinuation happens
Note: few older adults were represented in this cohort, and I’m sure data toxicity rates would be even higher at many centers in the community.”
Authors: Veronica Mears, Nikolas Naleid, Omkar Pawar, Jennifer Selfridge, Madison Conces, Melissa Lumish, David Bajor, Amit Mahipal, Sakti Chakrabarti.
More posts featuring Ramy Sedhom.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023